Mandate

Vinge advises Vicore Pharma in connection with a directed share issue

December 04, 2018 Capital Markets and Public M&A

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs. 

The share issue is directed to a number of selected Swedish and international long-term institutional investors and sector specialist funds, on the basis of a book building procedure conducted by DNB Markets, goetzpartners securities and Zonda Partners.

Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company’s shares are admitted to trading on Nasdaq First North. 

Vinge’s team has consisted of Jesper Schönbeck, Johan Winnerblad, Nils Fredrik Dehlin, Amanda Knutsson and Emelie Svanberg.

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Helsingborg AB, MOORE Allegretto AB and MOORE Ranby AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Helsingborg AB, MOORE Allegretto AB and MOORE Ranby AB.
September 18, 2025

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025